An investigation has uncovered alarming issues including increased mortality rates, absent safety records, dubious efficacy, ...

An FDA advisory committee has delivered a strong endorsement to Eli Lilly’s Alzheimer’s disease therapy donanemab, voting unanimously that the safety and efficacy of the amyloid-busting drug ...

Eli Lilly finally has FDA approval for its amyloid-busting Alzheimer’s disease therapy donanemab and will launch ... course would cost $12,522 while the drug would cost $48,696 for patients ...

Last week, a congressional report found that FDA's approval of a similar Alzheimer's drug called Aduhelm — also from Biogen and Eisai — was “rife with irregularities,” including a number ...

The safety and effectiveness of donanemab - an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA) - is called into question in an investigation published by The BMJ today.

The U.S. Food and Drug Administration (FDA) approved Kisunla™ (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company's (NYSE: LLY) Alzheimer's treatment for ...

The safety and effectiveness of donanemab - an Alzheimer's drug recently approved by the US Food & Drug Administration (FDA) - is called into question in an investigation published by The BMJ today.

The SEC concluded that Cassava Sciences falsified data in its Alzheimer’s clinical trials. Now the FDA needs to act, ...

The S.E.C. alleged shortcomings in research said to support the drug, and its developer agreed to a $40 million settlement.

In a study led by the Johns Hopkins University School of Medicine and Tufts University School of Medicine, researchers show ...

3, 2024 — An international team of researchers have made a promising breakthrough in the development of drugs to treat Alzheimer's Disease. For the first time, scientists have developed a drug ...

Discovery may offer new therapeutic target for development of new drugs against Alzheimer's and other neurodegenerative disorders.